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Palazzo E, Guida F, Migliozzi A, Gatta L, Marabese I, Luongo
L, Rossi C, de Novellis V, Ferna´ndez-Sa´nchez E, Soukupova M,
Zafra F, Maione S. Intraperiaqueductal gray glycine and D-serine
exert dual effects on rostral ventromedial medulla ON- and OFF-cell
activity and thermoceptive threshold in the rat. J Neurophysiol
102: 3169 –3179, 2009. First published September 23, 2009;
doi:10.1152/jn.00124.2009. We have studied the involvement of the
N-methyl-D-aspartate receptor (NMDAR) glycine site and the strych-
nine-sensitive glycine receptor (GlyR) in the ventrolateral periaque-
ductal gray (VL-PAG) on nociceptive behavior (tail flick) and pain-
related changes on neuronal activity in the rostral ventromedial me-
dulla (RVM). Glycine or D-serine increased the tail-flick latency,
reduced OFF-cell pause, and delayed its onset and increased the time
between the onset of the OFF-cell pause and the tail withdrawal.
Conversely, they decreased the ongoing activity of the ON cell, the
tail-flick–induced ON-cell firing, whereas they delayed the onset of
increased tail-flick–induced ON-cell firing. Also, glycine or D-serine
reduced the interval between the onset of the increased ON-cell firing
and tail withdrawal. Whereas 7-Cl-kynurenic acid (7-Cl-KYN) pre-
vented such effects, strychnine did not do so. A higher dose of
7-Cl-KYN or strychnine was per se able to reduce or increase tail-flick
latency and increase or reduce ON-cell activities, respectively. A
higher dose of glycine was hyperalgesic in the presence of 7-Cl-KYN,
whereas such an effect was prevented by strychnine. These data
suggest 1) a dual role of glycine in producing hyperalgesia or anal-
gesia by stimulating the GlyR or the NMDARs within the VL-PAG,
respectively; 2) consistently that RVM ON and OFF cells display
opposite firing patterns to the stimulation of the VL-PAG NMDAR
glycine site and GlyR activation; and 3) a tonic role of these receptors
within the VL-PAG–RVM antinociceptive descending pathway.
I N T R O D U C T I O N
It has been recently shown that glycine induces hyponoci-
ception when microinjected into the periaqueductal gray
(PAG) (Martins et al. 2008), a well-known antinociceptive area
whose stimulation evokes analgesia (Reynolds 1969). The
analgesic effect of glycine within the PAG could appear
controversial due to the fact that glycine is one of the most
commonly used fast inhibitory neurotransmitters in the brain
through the stimulation of specific strychnine-sensitive recep-
tor chloride channels (GlyRs) (Lynch 2009).
However, together with D-serine, glycine also acts as an
endogenous and obligatory coagonist of glutamate—the major
excitatory neurotransmitter within the CNS at the N-methyl-D-
aspartate receptor (NMDAR) glycine site (Hashimoto et al.
1993; Johnson and Ascher 1987; Parson et al. 1998; Schell et
al. 1997). Thus glycine also acts as an excitatory neurotrans-
mitter when it binds to the glycine site on the NMDAR.
D-Serine, however, has a different pharmacological profile,
since it binds only to the NMDAR glycine site. Having the
potential to act either as an inhibitory or as an excitatory
neurotransmitter, the site of action of glycine on NMDARs or
GlyR at the PAG level is crucial in pain modulation. PAG is a
key area of the antinociceptive descending pathway (Behbe-
hani 1995; Fields 2000), which includes the rostral ventrome-
dial medulla (RVM) as an intermediate station, projecting to
the dorsal horn spinal cord (Basbaum and Fields 1984; Fields
et al. 1995), thus regulating pain transmission.
The supraspinal levels of glycine and D-serine (De Miranda
et al. 2002; Wolosker et al. 1999a,b) in the brain have been
shown to be relatively higher (Hashimoto et al. 1995) than
those that are necessary to stimulate the NMDAR and it is
possible that, as shown for D-serine (Schell et al. 1995), much
of the PAG glycine could act on the NMDARs. Although no
conclusive evidence exists for supporting this hypothesis, or
even to suggest any interaction of glycine on NMDARs, it is
interesting that glycine transporter-1 (GLYT1) has been iden-
tified in the postsynaptic densities of asymmetric synapses
(Cubelos et al. 2005), a sort of synaptic organization for
concentrating glycine in the microenvironment around the
NMDARs (Lim et al. 2004). However, most of the studies on
glycine or D-serine regarding NMDAR modulation have been
limited to in vitro systems; how and whether glycine and
D-serine in the PAG may affect behavioral pain threshold and
the activity of RVM neurons responding specifically to noci-
ceptive stimuli are still poorly understood. In this study, we
have aimed to further clarify the effect of intra-PAG microin-
jections of glycine or D-serine, either alone or in combination
with strychnine or 7-Cl-kynurenic acid (7-Cl-KYN), in lightly
anesthetized rats, on 1) nociceptive reflexes to heat in the
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tail-flick test and 2) spontaneous and tail-flick–related activities
of Neutral, OFF, and ON cells of the RVM.
M E T H O D S
Animals
In all, 280 Wistar male rats (250–300 g) were used in this study.
Rats were housed 3 per cage under controlled illumination (12:12-h
light:dark cycle; light on 6:00 am) and environmental conditions
(ambient temperature: 20–22°C; humidity: 55–-60%) for 1 wk
before the commencement of experiments. Rat chow and tap water
were available without restriction. The experimental procedures were
approved by the Animal Ethics Committee of the Second University
of Naples. Animal care was in compliance with Italian Legislative
Decree DL 116/92 and European Commission Directive L358/1,
18/12/86 regulations on the protection of laboratory animals. All
efforts were made to minimize animal suffering and to reduce the
number of animals used.
Surgical preparation for intra-PAG microinjections
To perform direct intra-ventrolateral (VL) PAG administrations of
drugs or respective vehicle, artificial cerebrospinal fluid (ACSF,
composition, in mM: KCl 2.5; NaCl 125; MgCl2 1.18; CaCl2 1.26),
rats were anesthetized with pentobarbital (50 mg/kg, administered
intraperitoneally) and a 26-gauge, 12-mm-long stainless steel guide
cannula was stereotaxically lowered until its tip was 1.5 mm above the
ventrolateral PAG by applying coordinates from the atlas of Paxinos
and Watson (1986) (anterior [A]: 7.8 mm; lateral [L]: 0.5 mm from
bregma; ventral [V]: 4.3 mm below the dura). VL-PAG was consid-
ered in this study, since previous studies have shown the presence of
excitatory output neurons projecting to OFF neurons in the RVM in
that area (Moreau and Fields 1986; Sandkulher and Gebhart 1984).
The cannula was anchored with dental cement to a stainless steel
screw in the skull. We used a David Kopf stereotaxic apparatus
(David Kopf Instruments, Tujunga, CA), with the animal positioned
on a homeothermic temperature-controlled blanket (Harvard Appara-
tus, Edenbridge, Kent, UK). Direct intra-VL-PAG administration of
drugs, or respective vehicle, was conducted with a stainless steel
cannula connected by a polyethylene tube to a 1-l 31-gauge syringe
(SGE Analytical Science, Austin, TX), inserted through the guide
cannula and extended 1.5 mm beyond the tip of the guide cannula to
reach the VL-PAG. Volumes of 200-nl drug solutions, or vehicle,
were injected into the VL-PAG over a period of 60 s and the injection
cannula was gently removed 2 min later.
RVM extracellular recordings and tail-flick test
After implantation of the guide cannula into the VL-PAG (see
preceding section), a tungsten microelectrode was stereotaxically
lowered through a small craniotomy into the RVM (anterior–posterior
[AP]: 11.5; L: 0.3; V: 9.9–10.9) (Paxinos and Watson 1986) to
record the activity of Neutral, ON, and OFF cells. The OFF cells were
identified by the characteristic pause when noxious stimulation was
applied (Fields et al. 1983; Heinricher et al. 1989) and the criterion
used for the onset of the OFF-cell pause was the interval between the
onset of heat application and the last action potential prior to the tail
flick. With respect to ON cells, they have been identified by a sudden
increased firing (spikes/s) beginning just prior to the occurrence of the
reflex. Neutral cells did not show any significant change in activity
associated with the tail withdrawal (Morgan et al. 2008). Anesthesia
was maintained with a constant, continuous infusion of propofol
(5–10 mg kg1 h1, intravenous). Anesthesia was adjusted so that
tail flicks were elicited with a constant latency of 4–5 s. A thermal
stimulus was elicited by a radiant heat source of a tail-flick unit
(model 7360; Ugo Basile, Varese, Italy) focused on the rat tail about
3–5 cm from the tip. The rat tail was placed over the surface of a
slightly projecting window receiving the infrared (IR) energy. Tail-
flick latency in seconds was determined by a timer connected to a
photoelectric cell that stopped the timer (and switched off the lamp)
upon movement of the tail, which was withdrawal. By using a
rheostat, the intensity of current through the filament and therefore of
the radiant heat emission could be controlled (Le Bars et al. 2001) and
adjusted at the beginning of each experiment to elicit a constant
tail-flick latency. The IR intensity in our experiments was set to 50
mW, corresponding to 50 mJ/s (1 mW in 1 s produces an energy of 1
mJ1; a joule can be transformed into calories by using the conversion
factor 0.239). Tail flicks were elicited every 5 min for 15 min (or 20
min only in the experiments with 10-min strychnine pretreatment)
prior to microinjecting drugs, or respective vehicle, into the VL-PAG.
Tail-flick latencies were monitored in the same rats subjected to RVM
ON- and OFF-cell recordings.
Extracellular single-unit recordings were made in the RVM with
glass-insulated tungsten filament electrodes (3–5 M; FHC, Bow-
doin, ME). The recorded signals were amplified and displayed on a
digital storage oscilloscope to ensure that the unit under study was
unambiguously discriminated throughout the experiment. Signals
were also fed into a window discriminator whose output was pro-
cessed by an interface CED 1401 (Cambridge Electronic Design
[CED], Cambridge, UK) connected to a Pentium III PC. Spike2
software (CED, version 4) was used to create peristimulus rate
histograms on-line and to store and analyze digital records of single-
unit activity off-line. Configuration, shape, and height of the recorded
action potentials were monitored and recorded continuously using a
window discriminator and Spike2 software for on-line and off-line
analysis. Once a Neutral, ON, or OFF cell was identified, we optimized
spike size before all treatments. This study included only neurons
whose spike configuration remained constant and could clearly be
discriminated from activity in the background throughout the exper-
iment, indicating that the activity from only one neuron was mea-
sured. Only one neuron was recorded from each rat.
Histology
At the end of the experiment, a volume of 200 nl of neutral red
(0.1%) was also injected into the VL-PAG 30–40 min before killing
the rat. Rats were then intracardially perfused with 200 ml phosphate
buffer solution (PBS) followed by 200 ml 10% formalin solution in
PBS. The brains were removed and immersed in a saturated formalin
solution for 2 days. The injection site was ascertained by using two
consecutive sections (40 m), one stained with cresyl violet to
identify nuclei and the other unstained to determine dye spreading.
Only those rats whose microinjected site was located within the
VL-PAG were used for data computation.
Recording sites were recognized with an electrolytic lesion at the
conclusion of the experiment. The rats were killed with an overdose
of pentobarbital and perfused with 10% formalin. Locations of all the
studied neurons were reconstructed and plotted on standardized sec-
tions. Cells located outside the RVM were excluded from the study.
Treatments
Groups of six to eight animals for the ON- and six to eight for the
OFF-cell recordings were used for each treatment, with each animal
used for a single-cell recording.
Rats receiving intra-VL-PAG administration of vehicle or different
doses of glycine or D-serine, alone or in combination with 7-Cl-KYN
or stychnine, were grouped as follows.
1. A group of rats was implanted with guide cannulae and received
an intra-VL-PAG microinjection of 200 nl of ACSF and served as a
control for the intra-PAG drug microinjections.
2. Groups of rats received intra-VL-PAG microinjection of glycine
(5 and 10 nmol), 7-Cl-KYN (1 and 2 nmol), or strychnine (1 and 2
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nmol) alone. Glycine (10 nmol) was also administered in combination
with 7-Cl-KYN (1 nmol) or strychnine (1 nmol). Additional groups of
rats received intra-VL-PAG microinjection of glycine (20 nmol)
either alone or coinjected with 7-Cl-KYN (1 nmol). Moreover, an-
other group of rats received glycine (20 nmol) in combination with
7-Cl-KYN (1 nmol) 10 min after strychnine (1 nmol).
3. Groups of rats received an intra-VL-PAG microinjection of
D-serine (2 and 4 nmol) alone or D-serine (4 nmol) in combination
with 7-Cl-KYN (1 nmol) or strychnine (1 nmol). Additional groups of
rats received an intra-VL-PAG microinjection of a higher dose of
D-serine (8 nmol), either alone or in combination with 7-Cl-KYN (1
nmol).
The doses of glycine, D-serine, or antagonists for intra-VL-PAG
were chosen on the basis of other previous in vivo studies (Berrino et
al. 1993; Martins et al. 2008; Matheus et al. 1994; Santos et al. 2006)
as well as our own. In particular, since to our knowledge no other
study has been published describing the effects of strychnine by using
a similar administration route in the PAG, we performed preliminary
experiments with several doses of strychnine to find minimal doses
able to change RVM cell activities or tail-flick latencies.
Drugs
7-Cl-kynurenic acid (7-Cl-KYN) and strychnine were purchased
from Tocris Cookson (Bristol, UK). Glycine and D-serine were pur-
chased from Sigma. All drugs were dissolved in ACSF, with final pH
7.2 for intra-PAG microinjection.
Statistics
The neuron responses, before and after intra-VL-PAG vehicle or
drug microinjections, were measured and expressed as spikes/s (Hz).
Background activity of neurons was measured between tail flicks. In
particular, basal values were obtained by averaging the activities
recorded in 50 s before the application of three consecutive thermal
stimulations (each stimulation trial was performed every 5 min). Four
thermal stimulations were considered only in the set of experiments
with 10-min strychnine pretreatment. Data are presented as means 
SE in neuron responses either of changes in withdrawal latencies (s,
tail-flick test) or changes in neuron response (extracellular record-
ings). Tail-flick–related ON-cell firing was calculated as the number of
spikes in the 2-s interval beginning 0.5 s before the tail flick, before
and after drug treatments. Furthermore, the time between the begin-
ning of ON-cell increase in frequency and the tail withdrawal was
calculated (s). The onset of the ON-cell burst was also calculated as the
time elapsed between the onset of the applied noxious radiant heat and
the beginning of the tail-flick–related increase in the cell frequency,
which was at least double that of baseline spontaneous activity.
We also performed analysis of tail-flick–related OFF-cell activities
before and after drug treatments. The latency to onset of the OFF-cell
pause (the interval between the onset of thermal stimulus and the last
spike) and the duration of the cell pause (the interval between the
pause onset and the first spike after the tail flick) were determined.
The interval between the onset of the ON-cell pause and the tail
withdrawal was also calculated (s).
Comparisons between pre- and post-treatment ongoing and tail-
flick–related cell activity changes were performed by repeated-mea-
sures ANOVA. Comparisons between groups of rats with different
treatments were performed by using Wilcoxon signed-ranks test. P 
0.05 was considered statistically significant.
R E S U L T S
Glycine and D-serine increased tail-flick latencies
Tail flicks were elicited every 5 min for 15 min prior to
microinjecting drugs or respective vehicle into the VL-PAG.
Data related to pretreatment intervals were considered as basal
tail-flick latencies (5.2  0.4 s). Intra-VL-PAG microinjection
of vehicle did not change the tail-flick latency compared with
basal values (4.9  0.7 s, n  20) (Fig. 1). Tail-flick latency
was significantly increased to 7.3 0.5 (P 0.05, n 15) and
9.4  0.7 s (P  0.05, n  14) or to 6.7  0.3 (P  0.05, n 
15) and 8.6  0.6 s (P  0.05, n  12) by intra-VL-PAG
microinjections of glycine (5 and 10 nmol) (Fig. 1A) or
D-serine (2 and 4 nmol) (Fig. 1B), respectively.
Coinjection with 7-Cl-KYN (1 nmol) prevented the effects
of glycine (10 nmol) (P 0.05, n 16) (Fig. 1A) and D-serine
(4 nmol) (P  0.05, n  14) (Fig. 1B). Strychnine (1 nmol)
FIG. 1. Tail-flick latencies before (predrug) and after (postdrugs) microin-
jections into the ventrolateral-periaqueductal gray (VL-PAG) of vehicle, gly-
cine (Gly), D-serine, strychnine (Stry), and 7-Cl-kynurenic acid (7-Cl-KYN).
A: the effects of glycine (5 and 10 nmol), or glycine (10 nmol) in combination
with strychnine (1 nmol) or 7-Cl-KYN (1 nmol). B: the effects of vehicle,
D-serine (2 and 4 nmol), or D-serine (4 nmol) in combination with strychnine
(1 nmol) or 7-Cl-KYN (1 nmol). C: the effects of vehicle, strychnine (1 and 2
nmol), or 7-Cl-KYN (1 and 2 nmol). D: the effects of glycine (20 nmol) alone
or in combination with 7-Cl-KYN (1 nmol) or glycine in combination with
7-Cl-KYN after pretreatment with strychnine (1 nmol). Each point represents
the mean  SE of 12–20 observations. Filled symbols indicate significant
differences vs. vehicle, glycine (10 nmol) (A), D-serine (4 nmol) (B), or glycine
in combination with 7-Cl-KYN (D). Values of P  0.05 were considered
statistically significant.
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failed to antagonize the effects of glycine (10 nmol, n  16)
(Fig. 1A) and D-serine (4 nmol, n  14) (Fig. 1B).
High doses of 7-Cl-KYN and strychnine decreased or
increased tail-flick latency, respectively
With respect to the effects of the highest doses of the
antagonists, we found that tail-flick latency significantly
increased to 7.2  0.5 s (P  0.05, n  14) with intra-VL-
PAG microinjection of strychnine (2 nmol), whereas it
decreased to 2.8  0.5 s with 7-Cl-KYN (2 nmol) (P  0.05,
n  14) (Fig. 1C).
A high dose of glycine (20 nmol) did not significantly
change tail-flick latency (4.2  0.3 s, n  15). Moreover,
tail-flick latency significantly decreased to 2.4  0.8 s with an
intra-VL-PAG microinjection of glycine (20 nmol) in combi-
nation with 7-Cl-KYN (1 nmol) (P  0.05, n  15) (Fig. 1D).
These latter effects were prevented by pretreatment with
strychnine (1 nmol) (P  0.05, n  16).
Glycine or D-serine decreased or increased the ongoing
activities of RVM ON and OFF cells, respectively
The results are based on RVM neurons at a depth of
8,870 –10,540 m from the surface of the brain, the location
of the neurons being in the nucleus raphe magnus, nucleus
reticularis gigantocellularis pars , and nucleus reticularis
paragigantocellularis (Fig. 2B). All recorded neurons were
spontaneously active and discharged with a mean frequency
(in spikes/s) of 6.3  0.8 (Neutral cells), 7.08  0.4 (ON
cells), and 8.1  0.5 (OFF cells). These neurons were iden-
tified by the characteristic OFF-cell pause and ON-cell burst of
activity just before tail-flick responses or by their nonre-
sponsiveness to noxious stimuli for the Neutral cells. Mi-
croinjections of glycine (5–10 nmol) into the VL-PAG
caused a dose-dependent decrease in the firing activity of
the ON cells, which was significant between 10 and 40 min
and maximal 25 min after administration of the 10 nmol
(P  0.05, n  7) (Fig. 3A). The same treatment produced
a very rapid significant increase in the firing activity of the
OFF cells, which was already significant after 5 min and
maximal after 15 min from administration of the 10 nmol
(P  0.05, n  7) (Fig. 3B). Similarly to glycine, microin-
jections of D-serine (2 and 4 nmol) into the VL-PAG caused
a dose-dependent decrease in the firing activity of the ON
cells that was significant between 15 and 40 min and max-
imal 25 min after administration of the 4 nmol (P  0.01,
n  6) (Fig. 3C) as well as a very rapid increase in the firing
activity of the OFF cells (Fig. 3D), which was significant
between 10 and 35 min and maximal 25 min after admin-
istration of the 4 nmol dose (P  0.01, n  6) (Fig. 3D).
Spontaneous activities of RVM Neutral neurons (n  6), as
identified by their nonresponsiveness to tail flick, were also
analyzed before and after intra-VL-PAG microinjection of
glycine (10 nmol) or D-serine (4 nmol), which failed to
cause any change in their spontaneous activity (6.5  0.7,
n  6 and 6.1  0.5 spike/s, n  6, respectively) (Fig. 4A).
Finally, microinjection of glycine (10 nmol) outside the
VL-PAG (Fig. 2A) did not change the ON-cell (7.1  0.4
spikes/s) and OFF-cell (7.9  0.6 spike/s) spontaneous ac-
tivity.
7-Cl-KYN prevented the effect of glycine or D-serine on
RVM ON- and OFF-cell ongoing activity, whereas strychnine
did not
The electrophysiological effects induced by glycine or D-
serine were significantly prevented when 7-Cl-KYN (1 nmol),
the antagonist of the NMDAR glycine site, was coinjected into
the VL-PAG (Fig. 3). In particular the coinjection with 7-Cl-
KYN (1 nmol) significantly prevented the effect of glycine (10
nmol) on the ON cell, an effect that started after 10 min and
lasted for the entire recording period (P  0.05, n  8) (Fig.
3A). The coinjection with 7-Cl-KYN (1 nmol) significantly
prevented the effect of glycine (10 nmol) on the OFF-cell
ongoing activity, an effect that was significant between 5 and
35 min (P  0.01 at 30 min postinjection, n  8) (Fig. 3B).
Moreover, the coinjection with 7-Cl-KYN (1 nmol) signifi-
cantly prevented the effect of D-serine (4 nmol) on the ON cells.
This effect was significant between 15 and 40 min (P  0.01
at 15 min postdrug coinjection, n  7) (Fig. 3C). The coinjec-
tion with 7-Cl-KYN (1 nmol) significantly prevented the effect
of D-serine on the ongoing activity of OFF cells, an effect that
was significant between 10 and 35 min (P  0.01 at 15 min,
n  7) (Fig. 3D). The effects of glycine or D-serine were not
prevented by strychnine (1 nmol), the selective GlyR antago-
nist (Fig. 3).
FIG. 2. Schematic illustration of the location of microinjection sites (A) and
rostral ventromedial medulla (RVM) ON- or OFF-cell recording sites (B).
Vehicle or drug microinjections were performed in the VL-PAG (filled
squares) (A). Open squares indicate the microinjection sites performed outside
the VL-PAG, which were associated neither with change in RVM cell activity
nor with tail-flick latency. Moreover, cell recordings were performed by
lowering a tungsten electrode into the RVM and ON-cell (filled circles) or
OFF-cell (open circles) sites (B) are shown. Many sites are not shown to avoid
overlapping of symbols. Distances (in mm) from the interaural line are
indicated.
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High doses of 7-Cl-KYN and strychnine conversely modified
the ongoing ON- and OFF-cell activity
Microinjection of a higher dose of 7-Cl-KYN (2 nmol) into
the VL-PAG caused an increase in the firing activity of the ON
cells, which was significant between 5 and 35 min and maxi-
mal 20 min after administration (P  0.01, n  7) (Fig. 4B).
It also caused a very rapid decrease in the firing activity of the
OFF cells, significant after 5 min and maximal 20 min after drug
administration (P  0.01, n  7) (Fig. 4C). Microinjections of
a higher dose of strychnine (2 nmol) into the VL-PAG caused
a decrease in the ongoing activity of the ON cells, which was
significant between 10 and 30 min and maximal 15 min after
administration (P  0.01, n  7) (Fig. 4B). Strychnine also
caused a very rapid, significant increase in the firing activity of
the OFF cells, which was maximal 15 min after the administra-
tion of strychnine (P  0.05, n  7) (Fig. 4C).
Effect of a high dose of glycine (but not of D-serine) on the
RVM cell firing was enhanced by 7-Cl-KYN and prevented
by strychnine
Microinjections into the VL-PAG of the highest dose of
glycine (20 nmol) caused a slight increase in the firing activity
of the ON cells, which was significant between 25 and 30 min
and maximal 25 min after administration (P  0.05, n  7)
(Fig. 5A). Glycine (20 nmol) also induced a decrease in the
firing activity of the OFF cells that was significant between 15
and 35 min and maximal at 20 min (P 0.05, n 7) (Fig. 5B).
These electrophysiological effects were accompanied by tran-
sient hyperalgesia, as measured with the tail-flick test (see the
preceding text). The effect of glycine (20 nmol) was signifi-
cantly enhanced when administered in combination with 7-Cl-
KYN (1 nmol). The effect on the ON cells was significant
between 5 and 35 min and maximal 15 min after administration
(P  0.01, n  8) (Fig. 5A). The effect on the OFF cells was
significant between 10 and 40 min and maximal 20 min after
administration (P  0.01, n  7) (Fig. 5B). Pretreatment with
strychnine (1 nmol) significantly prevented these effects on the
ON (P  0.01, n  8) and OFF cells (P  0.01, n  8) (Fig. 5,
A and B).
Conversely, microinjection into the VL-PAG of the high-
est dose of D-serine (8 nmol) decreased the firing activity of
the ON cells, which was significant between 5 and 30 min
and maximal 10 min after administration (P  0.05, n  7).
It increased the OFF-cell firing activity, which was significant
between 10 and 20 min and maximal at 15 min (P  0.05,
n  6) (not shown). These electrophysiological effects were
accompanied by analgesia measured by the tail-flick test
(not shown).
Glycine or D-serine modified tail-flick–related RVM cell
activities and tail withdrawal
Glycine and D-serine both modified tail-flick–related ON- and
OFF-cell activity. Glycine (5 nmol) significantly (P 0.05, n
7) changed the onset of the ON-cell burst (3.3  0.4 vs. 5.7 
0.5 s), whereas glycine (10 nmol) strongly reduced the ON-cell
burst activity (from 14.5 3.7 to 5.2 1.4 spikes/s; P 0.05,
n 7) (Fig. 6E) and significantly decreased the duration of the
OFF-cell pause (from 6.5  1.7 to 2.1  0.3 s) (P  0.05, n 
7) (Fig. 6E). Glycine (10 nmol) also delayed the onset of
OFF-cell pause (from 2.8  0.4 to 6.5  0.7 s; P  0.05, n 
7). D-Serine (4 nmol) significantly delayed the onset of the
ON-cell burst (2.6  0.4 vs. 5.3  0.6 s; P  0.05, n  6) and
shortened the time between the onset burst of the ON cell and
tail withdrawal latency (1.2  0.6 vs. 0.6  0.4 s; P  0.05,
n  6), whereas it significantly decreased the duration of the
OFF-cell pause (from 6.2  1.1 to 2.4  0.4 s; P  0.05, n 
6) (Fig. 6F). D-Serine (4 nmol) significantly inhibited tail-
flick–induced ON-cell peak firing (from 16.5 2.4 to 4.2 0.6
spikes/s; P  0.05, n  6) (Fig. 6F), delayed the onset of
OFF-cell pause (from 2.9  0.6 to 6.2  0.8 s; P  0.05, n 
6), and delayed the time between the onset of the OFF-cell pause
and the tail withdrawal (from 1.1  0.5 to 1.9  0.4 s; P 
0.05, n  6) (Fig. 6).
FIG. 3. Effect of vehicle, glycine, and
D-serine on the spontaneous firing of RVM
ON (A, C) or OFF (B, D) cells. A and B: the
effect of intra-VL-PAG administration of
vehicle, glycine (5 and 10 nmol), or glycine
(10 nmol) in combination with strychnine (1
nmol) or 7-Cl-KYN (1 nmol). C and D: the
effect of intra-VL-PAG administration of
D-serine (2 and 4 nmol) alone or D-serine (4
nmol) in combination with strychnine (1
nmol) or 7-Cl-KYN (1 nmol). The arrows
indicate drug microinjections. Each point
represents the mean  SE of 6–8 neurons.
Filled symbols indicate significant differences
vs. vehicle and vs. Gly (10 nmol) (A, B) and
D-serine (4 nmol) (C, D). P values0.05 were
considered statistically significant.
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Coadministration of a high dose of glycine with 7-Cl-KYN
modified tail-flick–related ON- and OFF-cell activity in a way
prevented by strychnine
The highest dose of glycine (20 nmol) did not modify the
tail-flick–related ON- and OFF-cell activity, whereas, in com-
bination with 7-Cl-KYN, it shortened the onset of the ON-
cell burst (3.1  0.4 vs. 1.5  0.4 s; P  0.05, n  8) and
increased the duration of the OFF-cell pause (from 3.2  1.2
to 5.9  0.6 s; P  0.05, n  7). Microinjection of glycine
(20 nmol) in combination with 7-Cl-KYN also increased
tail-flick–induced ON-cell peak firing (from 10.5  6.2 to
17.5  2.8 spikes/s; P  0.05, n  8) and shortened the
onset of OFF-cell pause (from 3.3  0.4 to 2.1  0.3 s; P 
0.05, n  7). This glycine-induced effect in combination
with 7-Cl-KYN was prevented by pretreatment with strych-
nine (1 nmol) (data not shown). Figure 6 shows examples of
ratemeter records that illustrate the effect of intra-VL-PAG
microinjection of glycine (10 nmol) and D-serine (4 nmol)
on either the ongoing activity or tail-flick–related burst of
activity of an identified RVM ON cell (Fig. 6, A and C) and
the ongoing activity or tail-flick–related pause of an identi-
fied RVM OFF cell (Fig. 6, B and D).
Highest doses of 7-Cl-KYN or strychnine modified
tail-flick–related changes on RVM cell activities
The highest doses of 7-Cl-KYN (2 nmol) or strychnine (2
nmol) used here modified tail-flick–related ON- and OFF-cell
activity (Fig. 7). 7-Cl-KYN (2 nmol) significantly shortened
the onset of the ON-cell burst (2.6  0.5 vs. 1.5  0.4 s, P 
0.05, n  7) and delayed the time between the onset of the
ON-cell burst and the tail withdrawal (0.9 0.4 vs. 1.8 0.5 s;
P  0.05, n  7), whereas it increased the duration of the
OFF-cell pause (from 5.1  1.7 to 8.7  0.9 s; P  0.05, n 
7) (Fig. 7E). 7-Cl-KYN also significantly increased tail-flick–
induced ON-cell peak firing (from 12.9  3.2 to 19.5  2.3
spikes/s; P 0.05, n 7) (Fig. 7E), although it also shortened
the onset of OFF-cell pause (from 2.7  0.4 to 1.5  0.4 s; P 
0.05, n 7) and shortened the interval between the onset of the
OFF-cell pause and the tail withdrawal (from 1.8 0.3 to 0.7
0.4 s; P  0.05, n  7).
Strychnine (2 nmol) significantly increased the ON-cell onset
of burst (3.5  0.5 vs. 6.7  0.8 s, P  0.05, n  7) and
shortened the time between the onset of the ON-cell burst and
the tail withdrawal (1.5  0.6 vs. 0.8  0.3 s; P  0.05, n 
7), while decreasing the duration of the OFF-cell pause (from
5.8 2.2 to 2.5 0.6 s; P 0.05, n 7) (Fig. 7F). Moreover,
strychnine decreased tail-flick–induced ON-cell peak firing
(from 13.2  4 to 7.4  2.5 spike/s, P  0.05, n  7) (Fig.
7F), delayed the onset OFF-cell pause, and delayed the time
FIG. 4. Effect of vehicle, glycine (10 nmol), or D-serine (4 nmol) on the
spontaneous firing of RVM neutral cells (A) or the effect of vehicle, strychnine
(1 and 2 nmol), or 7-Cl-KYN (1 and 2 nmol) on the ON (B) or OFF (C) cell
ongoing activity. The arrows indicate drug microinjections. Each point repre-
sents the mean  SE of 6–8 neurons. Filled symbols indicate significant
differences vs. vehicle. P values 0.05 were considered statistically signifi-
cant.
FIG. 5. Effect of vehicle, glycine (20 nmol) alone or in combination with
7-Cl-KYN (1 nmol), or Gly and 7-Cl-KYN in combination with strychnine (1
nmol) on RVM ON (A) and OFF (B) spontaneous cell firing. The black arrow
indicates the administrations of vehicle, glycine, or glycine in combination
with 7-Cl-KYN; the white arrow indicates strychnine 10 min pretreatment.
Each point represents the mean  SE of 6–8 neurons. Filled symbols indicate
significant differences vs. vehicle vs. Gly (20 nmol) alone or in combination
with 7-Cl-KYN (1 nmol). P values 0.05 were considered statistically signif-
icant.
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between the onset of the OFF-cell pause and the tail withdrawal
(0.9  0.3 to 1.8  0.7 s, P  0.05, n  7). Figure 7 shows
examples of ratemeter records that illustrate the effect of
intra-VL-PAG microinjection of 7-Cl-KYN (2 nmol) and
strychnine (2 nmol) on either the ongoing activity or tail-flick–
related burst of activity of an identified RVM ON cell (Fig. 7, A
and C) and ongoing activity or tail-flick–related pause of an
identified RVM OFF cell (Fig. 7, B and D).
D I S C U S S I O N
Thermal nociceptive responses and in vivo electrophysio-
logical findings in this study provide evidence that glycine and
D-serine—endogenous coagonists at the strychnine-insensitive
glycine-recognition site on the NMDAR (Furukawa and
Gouaux 2003; Johnson and Ascher 1987)—can modulate pain
at the level of the VL-PAG in the rat. VL-PAG–RVM circuitry
constitutes a main part of the endogenous antinociceptive
pathway that inhibits pain. Different pain-responding neurons
are found in the RVM: pain stimuli increase ON-, inhibit OFF-,
and do not affect Neutral-cell activity (Fields and Basbaum
1994; Fields et al. 1991). The ongoing and tail-flick–related
activities of these cells, with particular regard to ON and OFF
cells, represent a suitable target to investigate the effect of
pain-modulating agents at the PAG level.
Interestingly, we observed that glycine exerted a dual dose-
dependent effect on RVM ON- and OFF-cell activity and on
thermoceptive threshold in the same rat, whereas D-serine did
not have such a dual effect. More specifically, we found that,
on the one hand, if D-serine always induced dose-dependent
and strychnine-insensitive analgesia, on the other hand, glycine
was capable of generating either analgesia through NMDAR
stimulation (obtained with doses 10 nmol) or hyperalgesia
through GlyR stimulation and was observed with only the
highest dose used. Such apparently different effects obtained
by the two endogenous and obligatory coagonists for the
NMDAR glycine site raise the need to bear in mind that any
possible effect induced by glycine in vivo could represent a
cumulative effect resulting from the recruitment of two fast
ionotropic receptors, which modulate neural activity in oppos-
ing manners (inhibitory or excitatory). It may therefore be
FIG. 6. Examples of ratemeter records that illustrate the effect of intra-PAG microinjection of glycine (10 nmol) (A, B) and D-serine (4 nmol) (C, D) on either
the ongoing or tail flick-related burst of activity of identified RVM ON cell (A, C) and ongoing or tail-flick–related pause of identified RVM OFF cell (B, D).
Intra-PAG microinjection of glycine (10 nmol) and D-serine (4 nmol) reduced the ongoing activity and the tail-flick–related burst of the ON cell (A, C). The same
treatments increased the ongoing activity and reduced the tail-flick–related pause of the OFF cell (B, D). Single oscilloscope traces, indicated by the long black
arrows, show the effect of tail-flick stimulation (small gray arrows) and tail reflex (small black arrows) on the ON cell increased frequency or OFF cell pause before
and 20 min after intra-PAG glycine (10 nmol) and D-serine (4 nmol) microinjections. Filled triangles indicate tail flick trials, 1-s bins. Scale bars indicate 5-min
or 2-s intervals for ratemeter records or single oscilloscope traces, respectively. E and F: population data (means  SE) related to the ON-cell firing (Hz) and
OFF-cell pause (s) after microinjection of glycine (E) or D-serine (F).
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conceivable that, depending on the preferential VL-PAG gly-
cine-recognition site stimulation (i.e., the GlyRs or the
NMDARs), the output PAG neurons projecting to the RVM
and impinging on the ON and OFF cells may affect the activity
of those cells differently with GlyR producing hyperalgesia and
NMDAR stimulation producing analgesia. Moreover, depending on
the site stimulated, GlyR or glycine site on NMDARs, glycine
induced hyperalgesia or analgesia. Importantly, microinjec-
tions of 7-Cl-KYN at a higher dose than that used in combi-
nation with glycine facilitate nociception and either increase or
decrease ON- and OFF-cell activity, respectively. This evidence
suggests that the NMDAR glycine site may play a tonic phys-
iological role on pain modulation within the VL-PAG–RVM
circuitry. This effect is consistent with our previous studies
showing that intra-PAG microinjection of selective NMDA
antagonists is capable of enhancing nociceptive behavior in
rodents (Palazzo et al. 2001, 2002).
Accordingly, when microinjected into the PAG, glycine or
D-serine decreased the ongoing activity of the pronociceptive
ON cells and increased the ongoing activity of the antinocicep-
tive OFF cells in the RVM in a way that was prevented by
coadministration with 7-Cl-KYN. This effect suggests that
stimulation of the NMDAR glycine site modified the activity of
PAG output neurons and either decreased or increased the
input required to modulate the spontaneous activities of ON and
OFF cells. The present finding that 7-Cl-KYN in the VL-PAG
blocked glycine- or D-serine–induced antinociception and the
related changes in the RVM cell activity suggests that the
effects of glycine or D-serine were related to the enhancement
of NMDAR-mediated neurotransmission. Since the ON cells
may facilitate nociception (Fields et al. 1991), a delayed onset
of the ON-cell burst as well as the shortened interval between
the onset of the ON-cell burst and tail withdrawal, with either
glycine or D-serine, might be expected to be critical events in
the occurrence of analgesia (Foo and Mason 2005; Heinricher
et al. 1989; Jinks et al. 2004). Indeed, pain transmission and
perception are constantly changing: increasing during periods
of ON-cell activity and decreasing when OFF cells are active
FIG. 7. Examples of ratemeter records that illustrate the effect of intra-PAG microinjections of 7-Cl-KYN (2 nmol) (A and B) or strychnine (Stry, 2 nmol)
(C and D) on either the ongoing activity or tail-flick–related change in the activity of identified RVM ON cell (A and C) and ongoing activity or tail-flick–related
pause of the identified RVM OFF cell (B and D). Intra-PAG microinjection of 7-Cl-KYN (2 nmol) increased the ongoing activity and the tail-flick–related
frequency of the ON cell (A). The same treatment reduced the ongoing activity and increased the tail-flick–related pause of the OFF cell (B). Intra-PAG
microinjection of strychnine (Stry, 2 nmol) reduced the ongoing activity and the tail-flick–related burst of the ON cell (C). The same treatment increased the
ongoing activity and decreased the tail-flick–related pause of the OFF cell (D). Single oscilloscope traces, indicated by the long black arrows, show the effect of
tail-flick stimulation (small gray arrows) and tail-flick reflex (black arrows) on the ON-cell activity or OFF-cell pause before and 20 min after strychnine or
7-Cl-KYN microinjections. Filled triangles indicate tail-flick trials, 1-s bins. Scale bars indicate 5-min or 2-s intervals for ratemeter records or single oscilloscope
traces, respectively. E and F: population data (means  SE) related to the ON-cell firing (Hz) and OFF-cell pause (s) after microinjection of 7-Cl-KYN (E) or
strychnine (F).
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(Clearly et al. 2008; Mason 2005; Ramirez and Vanegas 1989).
Consistent with their effect on ON cells, intra-PAG microinjec-
tions of glycine or D-serine delayed the onset of the OFF-cell
pause, but shortening its duration and increasing the time
between the onset of the pause and tail withdrawal. This is
further confirmation of how critical the involvement of both ON
and OFF cells is in PAG–RVM-mediated analgesia (Clearly et
al. 2008; de Novellis et al. 2005; Heinricher and Tortorici
1994; Maione et al. 2006; McGaraughty and Heinricher 2002).
Significantly, when the highest dose of glycine (20 nmol)
was microinjected into the VL-PAG, it increased the ongoing
activity of the pronociceptive ON cells and decreased the
ongoing activity of the antinociceptive OFF cells in the RVM.
This effect appeared with a long latency, making one wonder
whether the observed effect was due to the drug diffusion to
other nuclei close to the VL-PAG. The anatomical controls
performed in the current study revealed that the diffusion
radius of 200-nl-volume microinjections was about 0.250–360
mm and VL-PAG has an horizontal axis of 1.36 mm and a
vertical one of 1.31 mm in the rat (Paxinos and Watson 1986).
Thus in spite of the diffusion the microinjected drug should
remain within the VL-PAG. Moreover, when some treatments
were intentionally or wrongly (discarded data) performed out-
side the PAG, they failed to produce any significant change in
either behavioral or RVM cell activity. However, it cannot be
absolutely excluded that the observed effects could include the
involvement and/or the contribution of adjacent areas (i.e.,
dorsal raphe, dorsolateral PAG).
The effect of the highest dose of glycine was dramatically
enhanced by blocking the NMDA glycine site receptor with the
lowest dose of 7-Cl-KYN and, accordingly, a hyperalgesic
effect was observed in the tail-flick test. This pain facilitatory
effect was in turn prevented by strychnine, assuming the
presence of functional GlyR in the PAG–RVM circuitries that,
similarly to -aminobutyric acid type A receptors in the PAG
(Moreau and Fields 1986), could be tonically involved in the
facilitation of pain transmission. Such evidence would suggest
that, depending on the GlyR or NMDA glycine recognition site
stimulation, glycine modifies the activity of PAG output neu-
rons affecting the spontaneous activities of ON and OFF cells,
thus causing hyperalgesia or analgesia. This possibility seems
further strengthened by the fact that, unlike glycine, D-serine,
which binds and stimulates the glycine site only on the
NMDAR (but not the GlyR) always induced analgesia. More-
over, the different roles played by these amino acids in the
PAG derive from the capability of D-serine, compared with
glycine, to increase (i.e., 2–3 min postmicroinjection) tail-flick
latency more rapidly, although both treatments induced rapid
electrophysiological effects. We speculate that these differ-
ences could be due to the selective NMDA-related effect of
D-serine (i.e., analgesia), compared with glycine, which is in
turn also able to modulate its own GlyRs. This makes it
possible that the two counteracting effects (i.e., analgesia or
hyperalgesia via NMDA or GlyR, respectively) conceal the
effect of one another and prevent any change in tail-flick
latency, consistent with a delayed inhibition of the pronocicep-
tive ON-cell activity. However, since glycine also induced a 7-
to 10-min delayed analgesia, it could be possible that the
NMDA-mediated effect may eventually prevail on the GlyR-
mediated one.
Consistent with other previous studies (Berrino et al. 1993;
Li and Han 2007; Sjo¨stro¨m et al. 2003), these data suggest that
the physiological level of glycine in the PAG might be in a
critical range, allowing the stimulation of a share of nonsat-
urated NMDARs in vivo. Indeed, considering that the EC50s of
D-serine or glycine for NR1–NR2A (postsynaptic) receptors
are known to be higher than those for NR1–NR2B (presynap-
tic) ones (Kew et al. 1998; Kutsuwada et al. 1992), one could
suppose that the postsynaptic (containing NR2A) nonsaturated
NMDA subtype receptors would mainly be recruited in vivo by
microinjecting glycine or D-serine into the PAG. Moreover,
with respect to the GlyRs, we provide in vivo evidence that
strychnine induced analgesia per se. However, an unanswered
question remains. A recent study has shown that when micro-
injected into the dorsolateral PAG (D-PAG), glycine was able
to induce hyponociception in awake and restrained rats; how-
ever, extremely high doses were required and hyperalgesia was
not induced (Martins et al. 2008). The differences between the
findings of Martins et al. (2008) and those of the current
research may be explained by the fact that the two studies were
performed in different PAG regions and experimental condi-
tions. Indeed, it should be considered that: 1) VL-PAG and
D-PAG work very differently, as demonstrated either by phar-
macological or electrical manipulations, and the same neuro-
transmitter (i.e., glutamate) can even generate opposite re-
sponses (Bandler et al. 1991; Carrive and Bandler 1991);
2) neural pain circuitry within the VL-PAG is classically
modulated by the opioid system, whereas the D-PAG instead
seems to be poorly regulated by opioids (Morgan and Liebe-
skind 1987); 3) two “pure analgesic regions,” both located in
the ventral PAG (the dorsal raphe nucleus and the ventrolateral
columnar organization of the PAG) have been recognized
(Fardin et al. 1984); 4) we performed the experiments in
anesthetized rats by continuous infusion of propofol, which is
able to affect both inhibitory and excitatory amino acid neu-
rotransmitter systems (Orser et al. 1994); and 5) finally, the
experiments by Martins et al. (2008) were performed in awake
and restrained animals, which implies a stress-induced modi-
fication of the nocifensive threshold (i.e., stress-induced anal-
gesia [SIA]). Considering that the D-PAG is critically involved
in the SIA genesis it might be possible that such a condition
partly contributed to the diminished ability of glycine to induce
hyperalgesia.
In conclusion, together with previously reported electro-
physiological, pharmacological, and anatomical findings,
this study provides evidence indicating that not only the
strychnine-insensitive glycine-recognition site on the
NMDAR, but also the strychnine-sensitive GlyRs, may have to-
nic roles in analgesia or hyperalgesia mediated by the VL-
PAG. Furthermore, this study highlights the close relationship
that exists between the strychnine-sensitive GlyRs and gluta-
mate NMDA-mediated neurotransmissions, adding further
complexity to the question of how fast amino acid excitatory
and inhibitory neurotransmitters might modulate pain and pos-
sibly several other functions within the PAG–RVM pathway.
Since our study and those of others underline the role of
glycine and D-serine in the modulation of the descending
antinociceptive pathway, new strategies for the development of
drugs targeting glycine-recognition site on NMDAR should be
aimed at pain control research.
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